GRDX
Entero Therapeutics, Inc.
NASDAQ: GRDX · HEALTHCARE · BIOTECHNOLOGY
$2.51
+17.29% today
Updated 2026-04-30
Market cap
$7.56M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-11.66
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Entero Therapeutics, Inc. (GRDX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $56.00 | $-1.01M | $-4.17M | $-4.53M | $-7.18M | $-10.87M | $-14.03M | $-11.22M | $-32.29M | $-22.34M | $-12.38M | $-9.22M |
| Capital expenditures | $0.00 | $191.00 | $24380.00 | $12355.00 | $32168.00 | $305473.00 | $24098.00 | $4167.00 | $10.32M | $0.00 | $500000.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | — | $1.10M | $2.48M | $1391.00 | $549425.00 | $1.37M | $769124.00 | $1.04M | $631555.00 |
| Free cash flow | $56.00 | $-1.01M | $-4.19M | $-4.55M | $-7.22M | $-11.17M | $-14.06M | $-11.23M | $-42.61M | $-22.34M | $-12.88M | $-9.22M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | $240965.00 |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — |